HAIC Plus QL1706 & Bevacizumab in Unresectable HER2-Negative ICC
HAIC Plus QL1706 & Bevacizumab in Unresectable HER2-Negative ICC
Recruiting · NCT07841574 · Registry updated 2026-09-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| HAIC Plus QL1706 & Bevacizumab in Unresectable HER2-Negative ICC | Neoplasms by Histologic Type, adenocarcinoma, carcinoma, cholangiocarcinoma, epithelial neoplasm, intrahepatic cholangiocarcinoma, neoplasm | Recruiting | Phase 2 | 2026-09-25 | NCT07841574 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Lianghe Lu | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Sun Yat-sen University Cancer Center | Guangzhou | China | 315 |